• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by MetaVia Inc.

    7/2/26 4:05:11 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email
    424B5 1 tm2618959d2_424b5.htm 424B5

     

    Filed pursuant to Rule 424(b)(5)

    Registration No. 333-278646

     

    PROSPECTUS SUPPLEMENT

    (To the prospectus supplement dated November 6, 2025) 

    (To prospectus dated April 23, 2024)

     

    Up to $4,000,000 of Common Stock

     

     

    METAVIA INC.

     

    This prospectus supplement (this “Prospectus Supplement”) supplements the prospectus supplement dated November 6, 2025 (the “Initial ATM Prospectus Supplement”) and the accompanying prospectus dated April 23, 2024 (the “accompanying prospectus”), relating to the offer and sale of shares of our common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $2,300,000 pursuant to the terms of an At The Market Offering Agreement (“Sales Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”). Through the date hereof, we have sold an aggregate of $2,126,303 of shares of our Common Stock through Ladenburg under the Sales Agreement.

     

    We are filing this Prospectus Supplement to amend the Initial ATM Prospectus Supplement and the accompanying prospectus to increase the aggregate offering price of up to $2,300,000 of shares of Common Stock that we were eligible to sell pursuant to the Sales Agreement. Pursuant to this Prospectus Supplement, we are registering the offer and sale of up to an aggregate offering price of up to $4,000,000 of shares of our Common Stock. This Prospectus Supplement should be read in conjunction with the Initial ATM Prospectus Supplement and the accompanying prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Initial ATM Prospectus Supplement and accompanying prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Initial ATM Prospectus Supplement and the accompanying prospectus, and any future amendments or supplements thereto.

     

    Our Common Stock is listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “MTVA.” The last reported sales price of our shares of Common Stock on July 1, 2026 was $1.45 per share.

     

    The aggregate market value of our Common Stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $18,438,694, based on 4,789,271 shares of Common Stock held by non-affiliates and a price of $3.85 per share, the last reported sale price per share of our Common Stock on Nasdaq on May 22, 2026. During the 12-calendar month period that ends on, and includes, the date of this Prospectus Supplement, we sold an aggregate of $2,126,303 of shares of our Common Stock pursuant to General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our securities in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75,000,000.

     

    Investing in shares of our Common Stock involves a high degree of risk. Please read carefully the information contained in or incorporated by reference under the heading “Risk Factors” beginning on page S-8 of the Initial ATM Prospectus Supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this Prospectus Supplement, the Initial ATM Prospectus Supplement and the accompanying prospectus.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this Prospectus Supplement, the Initial ATM Prospectus Supplement, or the accompanying prospectus. Any representation to the contrary is a criminal offense.

     

    Ladenburg Thalmann

     

    The date of this Prospectus Supplement is July 2, 2026

     

     

     

    Get the next $MTVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTVA

    DatePrice TargetRatingAnalyst
    9/4/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $MTVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/4/25 4:01:12 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    5/20/25 4:16:39 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tursi James Patrick was granted 17,186 shares, increasing direct ownership by 508% to 20,568 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/8/26 6:33:59 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strickland D Gordon was granted 17,186 shares, increasing direct ownership by 414% to 21,339 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/8/26 6:33:28 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Salsbury Michael was granted 17,186 shares, increasing direct ownership by 414% to 21,338 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/8/26 6:32:08 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

    All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mgTopline Data Remains on Track for Fourth Quarter 2026CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts. DA-1726 is a novel oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase 1 p

    7/9/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

    NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD

    6/26/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Industrial Specialties

    Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

    6/23/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Industrial Specialties

    $MTVA
    SEC Filings

    View All

    MetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    7/9/26 8:35:31 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    7/2/26 4:06:39 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by MetaVia Inc.

    424B5 - MetaVia Inc. (0001638287) (Filer)

    7/2/26 4:05:11 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on MetaVia with a new price target

    H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    9/4/25 9:02:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on MetaVia with a new price target

    H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    12/30/24 7:25:48 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Leadership Updates

    Live Leadership Updates

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Wednesday, June 24, 2026 at 10:30 am ET. This will be a live, interactive online forum where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast wi

    6/17/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

    POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced the appointment of Mark Glickman, Steven D. Sonenreich, and Rayna Lesser Hannaway to its Board of Directors, effective as of June 5, 2026. In connection with their appointment to the Board of Directors, Mr. Sonenreich has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Committee, Ms. Hannaway has been appointed as a member of the Audit Committee and the Corporate Governance and Nominating Commit

    6/9/26 7:00:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET. This will be a live, interactive online event where investors are invited to ask the company questions

    3/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care